AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERIBULIN MESYLATE IN PREVIOUSLY TREATED SUBJECTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA (STUDY E7389-J081-217):